Literature DB >> 30733618

Dementia in Down syndrome: unique insights for Alzheimer disease research.

Ira T Lott1, Elizabeth Head2.   

Abstract

Virtually all adults with Down syndrome (DS) show the neuropathological changes of Alzheimer disease (AD) by the age of 40 years. This association is partially due to overexpression of amyloid precursor protein, encoded by APP, as a result of the location of this gene on chromosome 21. Amyloid-β accumulates in the brain across the lifespan of people with DS, which provides a unique opportunity to understand the temporal progression of AD and the epigenetic factors that contribute to the age of dementia onset. This age dependency in the development of AD in DS can inform research into the presentation of AD in the general population, in whom a longitudinal perspective of the disease is not often available. Comparison of the risk profiles, biomarker profiles and genetic profiles of adults with DS with those of individuals with AD in the general population can help to determine common and distinct pathways as well as mechanisms underlying increased risk of dementia. This Review evaluates the similarities and differences between the pathological cascades and genetics underpinning DS and AD with the aim of providing a platform for common exploration of these disorders.

Entities:  

Mesh:

Year:  2019        PMID: 30733618      PMCID: PMC8061428          DOI: 10.1038/s41582-018-0132-6

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  211 in total

1.  BACE2 expression increases in human neurodegenerative disease.

Authors:  Christopher J Holler; Robin L Webb; Ashley L Laux; Tina L Beckett; Dana M Niedowicz; Rachel R Ahmed; Yinxing Liu; Christopher R Simmons; Amy L S Dowling; Angela Spinelli; Moshe Khurgel; Steven Estus; Elizabeth Head; Louis B Hersh; M Paul Murphy
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

2.  Early senile dementia in mongoloid idiocy.

Authors:  G A JERVIS
Journal:  Am J Psychiatry       Date:  1948-08       Impact factor: 18.112

3.  The pathological association between Down syndrome and Alzheimer disease.

Authors:  D M Mann
Journal:  Mech Ageing Dev       Date:  1988-05       Impact factor: 5.432

4.  Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein.

Authors:  G G Glenner; C W Wong
Journal:  Biochem Biophys Res Commun       Date:  1984-05-16       Impact factor: 3.575

Review 5.  Amyloid toxicity in Alzheimer's disease.

Authors:  Allison B Reiss; Hirra A Arain; Mark M Stecker; Nicolle M Siegart; Lora J Kasselman
Journal:  Rev Neurosci       Date:  2018-08-28       Impact factor: 4.353

Review 6.  Down syndrome, beta-amyloid and neuroimaging.

Authors:  Elizabeth Head; Alex M Helman; David Powell; Frederick A Schmitt
Journal:  Free Radic Biol Med       Date:  2017-09-19       Impact factor: 7.376

Review 7.  The discovery of Alzheimer-causing mutations in the APP gene and the formulation of the "amyloid cascade hypothesis".

Authors:  John Hardy
Journal:  FEBS J       Date:  2017-04       Impact factor: 5.542

8.  Down syndrome and Alzheimer's disease: Common pathways, common goals.

Authors:  Dean Hartley; Thomas Blumenthal; Maria Carrillo; Gilbert DiPaolo; Lucille Esralew; Katheleen Gardiner; Ann-Charlotte Granholm; Khalid Iqbal; Michael Krams; Cynthia Lemere; Ira Lott; William Mobley; Seth Ness; Ralph Nixon; Huntington Potter; Roger Reeves; Marwan Sabbagh; Wayne Silverman; Benjamin Tycko; Michelle Whitten; Thomas Wisniewski
Journal:  Alzheimers Dement       Date:  2014-12-12       Impact factor: 21.566

9.  Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: redox proteomics analysis of human brain.

Authors:  Fabio Di Domenico; Raffaella Coccia; Annalisa Cocciolo; M Paul Murphy; Giovanna Cenini; Elizabeth Head; D Allan Butterfield; Alessandra Giorgi; Maria Eugenia Schinina; Cesare Mancuso; Chiara Cini; Marzia Perluigi
Journal:  Biochim Biophys Acta       Date:  2013-04-18

Review 10.  The amyloid hypothesis of Alzheimer's disease at 25 years.

Authors:  Dennis J Selkoe; John Hardy
Journal:  EMBO Mol Med       Date:  2016-06-01       Impact factor: 12.137

View more
  79 in total

Review 1.  The vexing complexity of the amyloidogenic pathway.

Authors:  Manuel A Castro; Arina Hadziselimovic; Charles R Sanders
Journal:  Protein Sci       Date:  2019-04-11       Impact factor: 6.725

2.  Challenges and Opportunities for Translation of Therapies to Improve Cognition in Down Syndrome.

Authors:  Sarah E Lee; Monica Duran-Martinez; Sabina Khantsis; Diana W Bianchi; Faycal Guedj
Journal:  Trends Mol Med       Date:  2019-11-07       Impact factor: 11.951

3.  Alzheimer-Related Cerebrovascular Disease in Down Syndrome.

Authors:  Patrick J Lao; José Gutierrez; David Keator; Batool Rizvi; Arit Banerjee; Kay C Igwe; Krystal K Laing; Mithra Sathishkumar; Fahmida Moni; Howard Andrews; Sharon Krinsky-McHale; Elizabeth Head; Joseph H Lee; Florence Lai; Michael A Yassa; H Diana Rosas; Wayne Silverman; Ira T Lott; Nicole Schupf; Adam M Brickman
Journal:  Ann Neurol       Date:  2020-10-09       Impact factor: 10.422

4.  Alzheimer's Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials.

Authors:  Michael S Rafii
Journal:  CNS Drugs       Date:  2020-08       Impact factor: 5.749

5.  Integrating Biomarker Outcomes into Clinical Trials for Alzheimer's Disease in Down Syndrome.

Authors:  M S Rafii; S Zaman; B L Handen
Journal:  J Prev Alzheimers Dis       Date:  2021

6.  Evolution of neuroinflammation across the lifespan of individuals with Down syndrome.

Authors:  Lisi Flores-Aguilar; M Florencia Iulita; Olivia Kovecses; Maria D Torres; Sarah M Levi; Yian Zhang; Manor Askenazi; Thomas Wisniewski; Jorge Busciglio; A Claudio Cuello
Journal:  Brain       Date:  2020-12-01       Impact factor: 13.501

7.  Blood-based biomarkers for Down syndrome and Alzheimer's disease: A systematic review.

Authors:  Melissa E Petersen; Sid E O'Bryant
Journal:  Dev Neurobiol       Date:  2019-09-03       Impact factor: 3.964

Review 8.  Down syndrome.

Authors:  Stylianos E Antonarakis; Brian G Skotko; Michael S Rafii; Andre Strydom; Sarah E Pape; Diana W Bianchi; Stephanie L Sherman; Roger H Reeves
Journal:  Nat Rev Dis Primers       Date:  2020-02-06       Impact factor: 52.329

9.  A new role for matrix metalloproteinase-3 in the NGF metabolic pathway: Proteolysis of mature NGF and sex-specific differences in the continuum of Alzheimer's pathology.

Authors:  Rowan Pentz; M Florencia Iulita; Maya Mikutra-Cencora; Adriana Ducatenzeiler; David A Bennett; A Claudio Cuello
Journal:  Neurobiol Dis       Date:  2020-10-30       Impact factor: 5.996

10.  The Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome.

Authors:  Ilaria Zuliani; Chiara Lanzillotta; Antonella Tramutola; Antonio Francioso; Sara Pagnotta; Eugenio Barone; Marzia Perluigi; Fabio Di Domenico
Journal:  Neurotherapeutics       Date:  2020-11-30       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.